Subsequent treatment for locally advanced non-small-cell lung cancer that progressed after definitive chemoradiotherapy and consolidation therapy with durvalumab: a multicenter retrospective analysis (TOPGAN 2021-02)

• Published in: Cancer chemotherapy and pharmacology 2023-07, Vol.92 (1), p.29-37
• Main Authors: Hasegawa, Tsukasa, Ariyasu, Ryo, Tanaka, Hisashi, Saito, Ryota, Kawashima, Yosuke, Horiike, Atsushi, Sakatani, Toshio, Tozuka, Takehiro, Shiihara, Jun, Saiki, Masafumi, Tambo, Yuichi, Sonoda, Tomoaki, Miyazaki, Akito, Uematsu, Shinya, Tsuchiya-Kawano, Yuko, Yanagitani, Noriko, Nishino, Makoto
• Format: Article
• Language: English
• Subjects: Cancer Research; Chemoradiotherapy; Chemotherapy; Consolidation; Immune checkpoint inhibitors; Kinases; Lung cancer; Medicine; Medicine & Public Health; Non-small cell lung carcinoma; Oncology; Original Article; Pharmacology/Toxicology; Platinum; Protein-tyrosine kinase; Radiation therapy; Small cell lung carcinoma; Therapy; Tyrosine
• ISSN: 0344-5704; 1432-0843
• DOI: 10.1007/s00280-023-04547-2

Purpose For patients with locally advanced non-small-cell lung cancer (LA-NSCLC) that progressed after definitive chemoradiotherapy (CRT) and durvalumab consolidation therapy, no subsequent standard treatment exists. The type of treatment selected for each timing of disease progression and its efficacy have not been investigated. Methods We retrospectively enrolled patients with LA-NSCLC or inoperable NSCLC that progressed after definitive CRT and durvalumab consolidation therapy at 15 Japanese institutions. Patients were classified into the following: Early Discontinuation group (disease progression within 6 months after durvalumab initiation), Late Discontinuation group (disease progression from 7 to 12 months after durvalumab initiation), and Accomplishment group (disease progression from 12 months after durvalumab initiation). Results Altogether, 127 patients were analyzed, including 50 (39.4%), 42 (33.1%) and 35 (27.5%) patients from the Early Discontinuation, Late Discontinuation, and Accomplishment groups, respectively. Subsequent treatments were Platinum plus immune checkpoint inhibitors (ICI) in 18 (14.2%), ICI in 7 (5.5%), Platinum in 59 (46.4%), Non-Platinum in 35 (27.6%), and tyrosine kinase inhibitor in 8 (6.3%) patients. In the Early Discontinuation, Late Discontinuation, and Accomplishment groups, 4 (8.0%), 7 (16.7%), and 7 (20.0%) patients were receiving Platinum plus ICI; 21 (42.0%), 22 (52.4%), and 16 (45.7%) were receiving Platinum, and 20 (40.0%), 8 (19.0%), and 7 (20.0%) were receiving Non-Platinum, respectively. No significant difference in progression-free survival was observed in the timing of disease progression. Conclusion In patients with LA-NSCLC hat progressed after definitive CRT and durvalumab consolidation therapy, subsequent treatment may change depending on the timing of disease progression.